William F. Young, Jr., MD, MSc, ELS
Professor of Medicine, Mayo Clinic College of Medicine,
Tyson Family Endocrinology Clinical Professor Chair,
Division of Endocrinology, Diabetes, Metabolism, & Nutrition Mayo Clinic Rochester, Minnesota USA.
Dr. Young is Professor of Medicine in the Mayo Clinic College of Medicine. As Chair of the Division of Endocrinology at Mayo Clinic he leads one of the largest endocrine departments in the world. He is a Past President of the Endocrine Society and is the current Chair of the American Board of Internal Medicine Specialty Board in Endocrinology. Dr. Young has published over 250 articles on endocrine hypertension and adrenal and pituitary disorders. He has been the recipient of multiple education awards and has presented at over 400 national and international meetings and he has been an invited visiting professor for more than 125 medical institutions.
Dr. Young is one of the most respected clinician- teacher and one of the most sought after speakers in the field of endocrinology.
Director, Research Program in Men’s health: Aging and Metabolism
Director, Boston Claude D. Pepper
Older Americans Independence Center, Brigham and Women’s Hospital
Brigham and Womens Hospital Endocrine RFB 2, 221 Longwood Ave, Boston MA 02115 617/732 5661
Dr. Bhasin is the Director of the Research Program in Men’s Health: Aging and Metabolism and the Director of the NIA funded Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies at the Brigham and Women’s Hospital besides Lecturer on Medicine, Harvard Medical School. Dr. Bhasin is an internationally recognized reproductive endocrinologist with expertise in testosterone biology, reproductive endocrinology, and human aging. He chaired the Endocrine Society’s Expert Panel for the development of Guidelines for Testosterone Therapy. He is the Chair of the American Board of Internal Medicine Endocrinology Subspecialty Board, and serves on the ABIM’s Board of Directors. He received his MD from the All India Institute of Medical Sciences in New Delhi, India, residency training at Northwestern University Medical School and fellowship training in Endocrinology and Nutrition at Harbor UCLA Medical Center in Los Angeles, CA. His pioneering research in androgen biology, diagnosis and treatment of androgen deficiency, and anabolic therapies for aging associated sarcopenia has been supported by several NIH funded grants.
Susan J Mandel,MD, MPH, FACP, FACE
Director, Clinical Endocrinology and Diabetes, University of Pennsylvania Health System
Professor of Medicine and Professor of Radiology
Perelman School of Medicine, University of Pennsylvania
4th floor West, Perelman Center for Advanced Medicine
3400 Civic Center Blvd Philadelphia, PA 19104
Dr. Mandel’s clinical and research interests include Graves’ Disease, Thyroid Cancer, Thyroid Disease and Pregnancy and Thyroid Nodules. Specific areas include the use of sonography in the evaluation of patients with thyroid nodules and the novel introduction of iodine-123 imaging in differentiated thyroid cancer. Dr. Mandel also directs the American Thyroid Association’s Advanced Neck Ultrasound course . Over the course of her nearly 30-year career, Dr. Mandel established the model for thyroid nodule evaluative services and was one of the first endocrinologists to teach neck ultrasound to endocrine practitioners.Her expertise and educational skills have been recognized with invitations for presentations not only by the American Association of Clinical Endocrinologists, The Endocrine Society, the American Thyroid Association, and other international Endocrine organizations, but also by professional radiology societies. She has been recipient of prestigious Don Martin Teaching Award from the University of Pennsylvania. Dr. Mandel is also a nationally recognized leader in the education of her peers.
John Newell-Price,MA PhD FRCP
Professor of Endocrinology and Honorary Consultant Physician
Academic Unit of Diabetes, Endocrinology & Metabolism
Department of Human Metabolism
The University of Sheffield and Royal Hallamshire Hospital
Beech Hill Road Sheffield S10 2RX
Prof. John Newell-Price MA PhD FRCP is Professor of Endocrinology and Consultant Honorary Physician Academic Unit of Diabetes, Endocrinology & Metabolism Dept of Oncology and Metabolism and The Medical School University of Sheffield Beech Hill Road, Sheffield. He has held esteemed positions as Chair and founder of the first National Institute of Health Research (NIHR), UK Endocrine Research Collaboration (9 Universities & 13 NHS Trusts) and is Research lead for Endocrinology, Sheffield Teaching Hospitals NHS Trust 2007 to date. He is Senior Editor ‘Clinical Endocrinology’ 2015-2018; Associate Editor of “Clinical Endocrinology” 2001-14; Editor of ‘The Endocrinologist” 2009-2011; Editorial Boards of 2 International Journals – Journal of Clinical Endocrinology and Metabolism 2008-2012, and Clinical Endocrinology 2001 to date. With 89 highly cited papers published in Peer reviewed journals, including in NEJM and Lancet; having five highest Scopus citations and Scopus H Index – 33. He has contributed 12 Chapters. He has delivered 53 invited lectures at Major International Conferences; 38 National Conferences. His main areas of research are in glucocorticoids – deficiency and excess, and neuroendocrine tumours in both clinical and basic angles.
V.Krishna C. Chatterjee
Professor and Head, Diabetes and Endocrinology Unit of Addenbrooke’s Hospital,Cambridge.
Director of Wellcome Trust Research.
Prof V.Krishna C. Chatterjee ,a doyen in the field of endocrinology and the President-Elect of the British Thyroid association for 2017. Throughout his distinguished career as academic clinician and researcher, he has received several accolades including the prestigious endocrine society International award for publication excellence in 2013. A distinguished teacher and Fellow of the Royal Society, his research footprint is spread across the Atlantic and he has guided several PhD Students who went on to become top researchers in thyroidology. Dr Chaterjee’s research revolves around unraveling the genetic disorders of nuclear receptors. He is a pioneer in the field of molecular endocrinology and his work has shed light on genetics of resistance to thyroid hormone and insulin. Prof Kris’ plenary on “Immunotherapy -induced endocrinopathy with reference to the thyroid” is a much awaited highlight of ESICON 2017.
Roy Taylor, FRCP,MD,MRCP,MB ChB
Professor of Medicine and Metabolism,
University of Newcastle and Director of Newcastle Magnetic Resonance Centre
Dr. Roy Taylor’s key research over 3 decades has combined development and innovation in clinical diabetes with pathophysiological research on important questions. Major outputs include reduction in blindness due to diabetes in the UK as a consequence of immense work on retinal imaging and creation of the National Screening Programme for Diabetic Eye Disease. He is recipient of several international laurels including the Harry Keen Rank Nutrition Prize lecture and Banting Lecture, Diabetes UK. His present area of interest is translational medical research in many disciplines and creating the Newcastle Magnetic Resonance Centre through which he initiated studies demonstrating that type 2 diabetes is a reversible state of overnutrition during the first 10 years after diagnosis.
Ambika P. Ashraf, MD, DCH, MBBS
Professor, Department of Pediatrics/ Pediatric Endocrinology, University of Alabama
Director, Pediatric Lipid Clinic Associate,Metabolic Bone Clinic
Division of Pediatric Endocrinology, CPP Suite M30,
1601 4P Birmingham, AL 35233
Dr. Ambika Ashraf is currently Professor, Department of Pediatrics/ Pediatric Endocrinology, University of Alabama. An American diplomat holder in Clinical Lipidology, she directs the only Pediatric Lipid Clinic in the state of Alabama. Her major research interests are bone metabolism – relationships of vitamin D on calcium homeostasis, insulin resistance, cardiovascular health in children and adolescents. She is also one of the core physicians of the multidisciplinary Pediatric Metabolic Bone Clinic at Children’s of Alabama. Her present research focuses on role of carbohydrate-restricted diet to reverse fatty liver in adolescents with obesity. She has 52 scientific publications and serves as editorial member of 5 international journals. Her research and teaching experience are valuable in this interesting new arena.
Thozhukat Sathyapalan,MD(General Medicine,Diabetes and Endocrinology)
Lead and Professor of Endocrinology in Hull York Medical School, University
Honorary Consultant Endocrinologist at Hull and East Yorkshire Hospitals NHS Trust, UK.
Dr. Thozhukat Sathyapalan is the Lead and Professor of Endocrinology in Hull York Medical School, University of Hull and Honorary Consultant Endocrinologist at Hull and East Yorkshire Hospitals NHS Trust, UK. His main area of interest is on modulation of cardiovascular risk through pharmacological and nutritional interventions in insulin resistant states such as obesity, polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus. He is interested in traditional as well as novel risk factors, specifically endocrine disruptors. He has presented his research findings consistently (more than 80 abstracts in the last 5 years) in various national and international conferences besides original publications (63 articles) published in international journals in journals including JCEM and Diabetes Care. His research work is supported by grants from public and commercial funding bodies totalling more than £3million. He serves in the editorial board of journals including Clinical Endocrinology, Scientific Reports (Nature) and British Journal of Diabetes. He has also authored 5 chapters in books and is regarded as a scholar in the field of reproductive endocrinology specifically Polycystic ovary disease.
Senior Consultant Endocrinologist
Director of the Osteoporosis and Bone Metabolism Unit at Singapore General Hospital
Dr Manju Chandran is a Senior Consultant Endocrinologist and Director of the Osteoporosis and Bone Metabolism Unit at Singapore General Hospital which is exclusively devoted to research and clinical care of metabolic bone disorders in Singapore. She is the Current Chairperson of the Chapter of Endocrinologists of the College of Physicians, Academy of Medicine, Singapore. She is on the Fracture, Diabetes and Bone and Rare Bone Disorders Working Groups of the Council of Scientific Advisors of the International Osteoporosis Foundation (IOF), and is a Past President of the Endocrine and Metabolic Society of Singapore (EMSS). Her research and clinical interests include Secondary Fracture Prevention, Diabetic, Renal and Rare Metabolic Bone Diseases, Secondary Osteoporosis and the use of new bio-imaging modalities in Osteoporosis. She has won numerous international awards including the IOF-ESCEO International Young Investigator Award for 2013, the prestigious International Osteoporosis Foundation Committee of National Societies Medal in 2015 and her Secondary Fracture Prevention Program at Singapore General Hospital- OPTIMAL was awarded the coveted Gold Star in the Global Capture the Fracture Campaign of the IOF in 2015.
Hans de Vries
Professor of Internal Medicine, University of Amsterdam
Dr J.H. de Vries is a professor of Internal Medicine, with expertise in clinical aspects of diabetes mellitus, at the University of Amsterdam’s Faculty of Medicine (AMC-UvA).Dr. de Vries specialises in internal medicine and endocrinology, and is a principal investigator at the AMC-UvA. He is also the leader of the PCDIAB Consortium, and previously directed the AP@home Consortium, both of which are European research projects working on the development of an artificial pancreas. In addition, he is programme adviser for the annual European Advanced Technologies and Treatments for Diabetes meeting and a member of the editorial boards of two scientific journals: Diabetes Technology & Therapeutics and the Journal of Diabetes Science and Technology.Dr. de Vries teaches courses in the Medicine, Internal Medicine and Endocrinology curricula, as well as refresher courses for diabetes nurses and general medical practice support staff.
Helen L. Baron,MD
Assistant Professor of Clinical Medicine
Present Director of the Bone Mineral Density Unit
Dr Helen L. Baron is Assistant Professor of Clinical Medicine ; Present Director of the Bone Mineral Density Unit, and Endocrinologist, USC Abdominal Organ (Liver, Kidney & Pancreas) Transplant Team, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. She specialises in Endocrinology, Diabetes, & Metabolism with additional interest in Improving Patient Care with Newer Insulins. She has vast experience in the pharmacology of Insulin therapy and has several years of experience as Clinical Research Assistant in projects involving inhaled and injectable newer insulins. Dr Baron serves as Chair, 7 South ICU Glycemic Control Performance Group. Dr Baron serves as Task force Member, Medical Error Reduction Team and Insulin in the Hospital Setting – Glycemic Control and Improved Outcomes, USC Keck Hospital, Los Angeles, California.A great speaker, Dr Baron has also been honored with Brautbar Teaching Award and USC Faculty Teaching Awards from Los Angeles, California, USA. She has delivered international and national invited lectures on Achieving Glycemic Control in the Hospital Setting and Understanding the Incretin System in Type 2 Diabetes.
Vlado Perkovic MBBS, PhD, FRACP, FASN
Professor of Medicine, Faculty of Medicine, UNSW Sydney and Executive Director,
The George Institute Australia. His teaching experience includes Nephrologist at The Royal Melbourne Hospital.
Dr Vlado Perkovic has done extensive research investigating the progression of kidney disease, and its complications. As first, senior or corresponding author, he has multiple publications in the Lancet, BMJ, Annals of Internal Medicine, PLoS Medicine and a range of specialty journals.His ongoing work as Principal investigator and Steering committee Member includes trials of glucose lowering in diabetes, beta blockers in dialysis patients, different dialysis intensity and a range of further systematic reviews. His research focus has been on cardiovascular risk factors and particular blood pressure. These include CREDENCE study (3700 people with diabetic nephropathy, canagliflozin vs placebo); ACTIVE Dialysis Trial (200 dialysis patients, more vs. less intense dialysis); CARMELINA trial (8600 patients with diabetes and nephropathy, linagliptin vs. placebo); CANVAS Trial (4300 patients with diabetes, canagliflozin vs. placebo); CANVAS-R Trial (5700 patients with diabetes, canagliflozin vs. placebo); SONAR Trial (4100 patients with diabetic nephropathy, Atrasentan vs. placebo);